Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN AND CLAVULANATE POTASSIUM versus AZLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN AND CLAVULANATE POTASSIUM versus AZLIN.
AMOXICILLIN AND CLAVULANATE POTASSIUM vs AZLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Azlin is a penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis.
500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.
1-2 grams intravenously every 4-6 hours; total daily dose up to 12 grams for serious infections.
None Documented
None Documented
Amoxicillin: ~1-1.5 hours; Clavulanate: ~1 hour. Prolonged in renal impairment.
Terminal elimination half-life is approximately 1.0–1.5 hours in adults with normal renal function; prolonged to 3–5 hours in moderate renal impairment (CrCl 10–50 mL/min) and up to 10 hours in severe renal impairment (CrCl <10 mL/min).
Renal: ~50-70% amoxicillin unchanged; ~25-40% clavulanate as metabolites. Fecal: minimal. Biliary: minor.
Renal excretion of unchanged drug (approximately 60-70% via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for <10%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic